**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 8892**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (14): Pancreatic cancer

**Novel strategies for managing pancreatic cancer**

Loc WS *et al*. Pancreatic cancer overview

Welley S Loc, Jill P Smith, Gail Matters, Mark Kester, James H Adair

**Welley S Loc,** Department of Chemistry, The Pennsylvania State University, University Park, PA 16802, United States

**Jill P Smith,** National Institute of Diabetes and Digestive and Kidney Disease, The National Institutes of Health, Bethesda, MD 20892, United States

**Jill P Smith,** Department of Medicine, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States

**Gail Matters,** Department of Biochemistry and Molecular Biology, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States

**Mark Kester, James H Adair,** Department of Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States

**James H Adair,** Departments of Materials Science and Engineering, and Bioengineering, The Pennsylvania State University, University Park, PA 16802, United States

**Authors contributions:** Loc W contributed by acquisition of data, drafting and writing of manuscript and redrawing figures, performing edits and final approval of submitted manuscript; Smith JP, Matters G, Kester M, and Adair JH contributed to the conception and design, data acquisition, critical and edits, and approval of final version for publication.

**Supported by** the National Institutes of Health (NIH) R01 grant 5R01CA167535-02

**Correspondence to:** **James H Adair, PhD,** Departments of Materials Science and Engineering, and Bioengineering, The Pennsylvania State University, University Park, 223 Hallowell Building, PA 16802, United States. jha3@ems.psu.edu

**Telephone:** +1-814-8636047 **Fax:** +1-814-8652917

**Received:** January 10, 2014 **Revised:** March 14, 2014

**Accepted:** May 12, 2014

**Published online:**

**Abstract**

With the incidence reports of pancreatic cancer increasing every year, research over the last several decades has been focused on the means to achieve early diagnosis in patients that are at a high risk of developing the malignancy. This review covers current strategies for managing pancreatic cancer and further discusses efforts in understanding the role of early onset symptoms leading to tumor progression. Recent investigations in this discussion include type 3c diabetes, selected biomarkers and pathways related to pancreatic intraepithelial neoplasia lesions, drug resistance, and advances in nanomedicine which may provide significant solutions for improving early detection and treatments in future medicine.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Pancreatic cancer; Diagnosis; treatment; Signaling pathways; Nanomedicine; Biomarkers

**Core-tip:** Pancreatic cancer is currently one of the most aggressive cancers without standard treatment for improving chances of long-term survival. This paper highlights significant research in translational nanomedicine and the challenges in treating pancreatic cancer.

Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Pancreatic cancer is responsible for over 40000 deaths every year in the United States, representing about 3% of the newly diagnosed cancer cases. However, pancreatic cancer is the fourth most common cause of cancer related death in the United States, predominantly affecting patients ages 60-80 years[[1-4](#_ENREF_1)]. Pancreatic ductal adenocarcinoma (PDAC) constitutes up to 95% of pancreatic malignancies[[4](#_ENREF_4)]. Due to poor prognosis and delayed treatment, survival rate during the first year of diagnosis is as low as 20% and decreases to 6% by the fifth year[[2](#_ENREF_2)]. Reasons for this poor prognosis are related in part to the chemoresistance of PDAC and inability of chemotherapeutic agents to penetrate the dense fibrotic microenvironment associated with this malignancy. Early detection may improve the outcome and is occasionally possible when small tumors in the head of the pancreas cause obstructive jaundice. However, only 10%-15% of patients are diagnosed in the early stages when surgical resection can be offered[[5](#_ENREF_5),[6](#_ENREF_6)]. Over 90% of subjects are diagnosed with PDAC in the advanced stages[[4](#_ENREF_4)].

In the past decade, many efforts have been made in translational cancer, particularly nanomedical avenues, to create novel approaches to drug delivery and understand the early developmental stages of pancreatic cancer. Such advances suggest that stem cell signaling pathways can be used as targets for drug delivery. To date methods of prevention, standard diagnosis, and treatment for pancreatic cancer remain ineffective in improving the survival rate of diagnosed patients. This review covers recent investigations on type 3c diabetes, selected genetic markers, and advances in nanomedicine for early diagnosis of pancreatic cancer.

**HISTOPATHOLOGY OF PANCREATIC CANCER**

Tumors are classified as invasive ductal carcinoma, intraductal papillary mucinous neoplasm, neuroendrocrine tumors, or islet cell tumors[[7](#_ENREF_7)]. Invasive ductal carcinoma is referred to as pancreatic ductal adenocarcinoma (PDAC). Pancreatic cells undergo (1) endoderm formation; (2) pancreatic morphogenesis; and (3) beta cell differentiation to endocrine and exocrine cells[[8](#_ENREF_8)]. Pancreatic intraepithelial neoplasia (PanIN) lesions are believed to be one of the precursors of PDAC that coincides with multiple successions of genetic mutations[[9](#_ENREF_9)]. These mutations are possibly provoked by inflammatory stimulus from alcohol abuse or metabolic syndrome[[10](#_ENREF_10)]. Based on the grade of dysplasia, PanIN lesions can be categorized as type 1A, 1B, 2, or 3, from minimum to severe expansion of immature cells at the ductal epithelium (Figure 1). Genetic defects that follow PanIN-2 and PanIN-3, involve the dysfunction of one or more tumor suppressor genes that result in aberrant signaling pathways driving pancreatic cancer[[1](#_ENREF_1),[9](#_ENREF_9),[11](#_ENREF_11)].

**SYMPTOMS ASSOCIATED WITH PDAC**

PDAC can be asymptomatic in the early stages for months or years. Unfortunately, symptoms of pancreatic cancer typically do not manifest until the disease is in an advanced stage[[13](#_ENREF_13)]. Patients experience a range of symptoms that are not pathognomonic features to pancreatic cancer. Traditional diagnoses highlight notable symptoms, including obstructive jaundice, abdominal and back pain, weight loss, anorexia, dyspepsia, gallbladder enlargement, migratory thrombosis (Trousseaux syndrome), subcutaneous fat necrosis (panniculitus), and hyperglycemia[[14](#_ENREF_14),[15](#_ENREF_15)].

Carcinoma of the head of the pancreas is often detected when small tumors compress the bile duct, resulting in obstructive jaundice in about 75% of subjects[[14](#_ENREF_14)]. Nausea, vomiting, lethargy and weight loss may also result from change of appetite, bowel habits, and cancer cachexia. While PDAC can cause abdominal and back pain, it is not uncommon for pancreatic cancer patients to have "painless" jaundice where symptoms are not immediately intrusive[[15](#_ENREF_15)]. On occasions, tumors of the pancreas invade the superior mesenteric vessels or splenic vein resulting in hemorrhage from varices.

Collective evidence supports the claim that type 3c diabetes is pancreatogenic diabetes and can be caused by chronic pancreatitis due to loss of functioning pancreatic islet cells or may occur as the result of a paraneoplastic phenomenon caused by pancreatic cancer. While further studies are needed to distinguish cancer-induced diabetes from diabetes caused by other exocrine pancreatic diseases, they are classified as two different types of diabetes mellitus by the American Diabetes Association[[16](#_ENREF_16),[17](#_ENREF_17)]. This paraneoplastic syndrome precedes most cancer-specific symptoms by several months or years before tumors become radiologically detectable[[17](#_ENREF_17)]. New-onset diabetes may also increase the likelihood of pancreatic cancer by 5 to 8 times, with approximately 1% of patients developing the cancer within three years. Progressive and unintentional weight reduction is associated with type 3c diabetes[[18](#_ENREF_18)]. Unlike type 2 diabetes that is associated with weight gain and obesity, patients with type 3c continue to lose weight as glycemic control worsens in parallel with cancer advancement (Figure 2A). Weight loss is an early event of type 3c that is attributed to either cachexia or loss of adipose tissue[[17](#_ENREF_17)]. Cachexia is a chronic physical wasting and malnutrition disease that results in more than 10% body weight loss in late cancer stages. When cachexia is absent or has yet to occur, patients rapidly lose weight by adipose tissue inflammation from interactions with pancreatic cancer (Figure 2B). Inflammation in adipose tissue can contribute to peripheral insulin resistance by altering adipocyte secretion and propagate pathogenic processes similar to type 2 diabetes. About 90% of the hormonal secretion from adipose tissue macrophages is comprised of inflammatory cytokines[[17](#_ENREF_17),[19](#_ENREF_19)]. The accumulation of inflammatory cytokines triggers abnormal adipocyte secretion and reduced hepatic insulin sensitivity. This reaction leads to an increase of leptin levels (related to the loss of appetite) and decrease in adiponectin. Leptin and adiponectin are primary precursors to insulin resistance in type 2 diabetes[[20-22](#_ENREF_20)], which can be regulated by limiting glucose intake and weight gain. Diet changes, such as reduction in carbohydrate intake, have minimal effect on pancreatic cancer-induced diabetes. Weight loss symptoms and diabetes will persist until the tumors are resected. One potential mediator of the cancer-associated diabetes is the over-expression of a pluripotent hormone adrenomedullin that mediates insulin resistance through the interaction of adrenomedullin receptors on β-cells[[17](#_ENREF_17)]. An increase in endogenous expression of adrenomedullin results in β-cell dysfunction which inhibits insulin secretion in the plasma and tumors.

The relationship between diabetes and pancreatic cancer has been studied since the early 1830s, but the biological significance of type 3c diabetes in relation to pancreatic cancer had not been acknowledged until recently[[23](#_ENREF_23)]. Early diagnosis of type 3c could potentially lead to early diagnosis and treatment of patients with pancreatic cancer months to years before the tumor appears radiologically. Early distinction between type 2 and type 3c diabetes requires a high level of awareness and expertise, and may lead to the earlier diagnosis of pancreatic cancer. Severe weight loss is also intimately associated with a variety of cancers and occasionally occurs several months prior to death[[24](#_ENREF_24)]. Thus, understanding the collective effects of type 3c is substantial in distinguishing pancreatic cancer from the diverse array of malignancies.

**DIAGNOSTIC TESTS AND BIOMARKERS**

Currently there are no adequate diagnostic tests for early detection of pancreatic cancer, and routine radiographic tests or endoscopic ultrasound screening is only recommended for those individuals with a family history of pancreatic cancer, chronic pancreatitis, precancerous lesions, or new-onset diabetes. Serological markers such carbohydrate antigen (CA)19-9, MIC-1, carcinoembryonic antigen, human chorionic gonadotropin β, and CA72-4 have also been of interest but lack sufficient sensitivity and specificity for effective early cancer detection[[25-28](#_ENREF_25)].

However, research continues to make progress on uncovering genetic markers that are responsible for notable pancreatic cancer cell phenotypes. Recently, the role of mucin-1 (MUC-1) in malignant cells was first reported to upregulate multi-drug resistance genes such as *ABCC1*, *ABCC3*, *ABCC5* and *ABCB1*[[29](#_ENREF_29)]. MUC-1 is a transmembrane glycoprotein that lines the apical surface of epithelial cells, normally present to protect the body from infectious pathogens. Overexpression of MUC-1 is found in patients with common cancers that include pancreatic [[30](#_ENREF_30)], breast[[31](#_ENREF_31)], ovarian[[32](#_ENREF_32)] and thyroid[[33](#_ENREF_33)] cancers. MUC1 overexpression may be and enabled by the phosphatidylinositol 3'-kinase/Akt signaling pathway, a pathway associated with chemotherapeutic drug resistance in other cancers[[34](#_ENREF_34)].

**GENETIC MUTATIONS ASSOCIATED WITH PANCREATIC CANCER**

While there are at least 25 altered genes related to cancer pathways (*i.e.,* cell adhesion, apoptosis, and replication), only a handful have been identified in pancreatic cancer studies[[35](#_ENREF_35),[36](#_ENREF_36)]. BCRA2 mutations are found in up to 10% of those with PDAC. A germline variant of the cholecystokinin-B gene has been identified in over 35% of patients with PDAC and predicts both risk and survival[[28](#_ENREF_28)]. Activated Kirsten-Ras (Kras*)* oncogene is harbored in > 95% of pancreatic cancer tumors and is critical in cell proliferation and apoptotic resistance to hostile microenvironments (in the presence of anti-cancer agents)[[1](#_ENREF_1)]. Activation of the Kras oncogene releases Ras proteins that initiate mitogen-activated protein (MAPK) cascades[[37-39](#_ENREF_37)]. MAPK participates in many critical cellular events, including cell division, response to surroundings, movement, and cell death. Mutated Kras is accepted as a "Driver" gene for pancreatic cancer that propagates a series of ongoing cellular signal transduction processes that cause uncontrollable proliferation and architectural abnormalities where acinar tissue is replaced with ductal lesions.

Kras mutations are also capable of reducing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity[[40](#_ENREF_40)]. Abnormalities are likely to occur at codon 12 (G12D), involving a point mutation of one glycine to aspartic acid (G12D), or glycine to valine (G12V). TRAIL is a transmembrane protein that can be proteolytically cleaved from the cell surface to mediate apoptosis and anti-tumor activities[[40](#_ENREF_40)]. Inhibitors that directly target oncogenic Kras have not yet been developed, but remain an active area of investigation. However, Kras mutations can trigger an enrichment of a cytokine receptor, osteoprotegerin (OPG), which directly inhibits TRAIL solubility and potentially induces apoptosis[[40](#_ENREF_40),[41](#_ENREF_41)]. Interestingly, increased OPG and TRAIL levels are also found in subjects with type 2 diabetes mellitus[[42](#_ENREF_42)], but connections to type 3c diabetes have not been implicated.

**SIGNALING PATHWAYS ACTIVATED IN PANCREATIC CANCER**

Oncogenes depend on various signaling pathways to initiate tumor formation. Since most attempts to directly inhibit oncogenes like Kras have failed, attention has shifted to other critical signaling pathways for targeted cancer therapy[[43](#_ENREF_43)]. The Notch pathway, for instance, exerts its biological influence by maintaining homeostasis during embryonic development in multicellular organisms[[44](#_ENREF_44)] and is important in development of the pancreas. The loss of Notch signaling in the pancreas results in premature differentiation of endocrine and exocrine cells. Therefore, this pathway is essential for determining the fate of functioning pancreatic cells in epithelial and non-epithelial tissues. However, controversy exists in literature as to whether the Notch pathway serves as a promoter for tumor progression or an inhibitor[[45](#_ENREF_45),[46](#_ENREF_46)]. Lateral inhibition mechanisms of the Notch pathway involve a group of receptors (Notch1, Notch2, Notch3, and Notch4), target, and ligand key components that contribute uniquely to PanIN progression[[46](#_ENREF_46)]. For example, deletion of the Notch1 receptor generally accelerates PanIN lesion development and lowers median survival in Pdx1-CreERT2;LSL-KrasG12D, Pdx1-Cre;KrasG12D , and Ptf1a-Cre;KrasG12D mouse models[[46-49](#_ENREF_46)]. The loss of the Notch2 receptor in Ptf1a-mouse models, however, halts lesion progression and increases chances of survival[[49](#_ENREF_49)]. Tumor inhibition was also reported in several studies where the up-regulation of Hes1 from activated Notch pathway suppresses the expression of p57, which prevents progenitors from undergoing premature differentiation and uncontrollable proliferation[[50](#_ENREF_50)]. Without harming healthy adult cells, tumor suppression was achieved in zebrafish by forcing exocrine pancreatic precursors through Notch signaling to inhibit acinar cell differentiation[[45](#_ENREF_45)]. Ongoing investigations on type 2 diabetes also imply that the Notch pathway is responsible for insulin-resistance in pancreatic cells (from the expression or inactivation of *Hes1* gene, Rbp-Jk protein ligand, and *Ngn3* gene)[[51](#_ENREF_51)]. The function of the Notch pathway during PDAC development is dependent on the targeted receptor and the genes expressed. Clearly, Notch signaling pathway targeted therapy serves as a potential target for treating pancreatic cancer. Such therapies must be exercised with caution since a wide variety of cells rely on ligand-dependent pathways for growth and survival.

Another important pathway activated by GTP-protein coupled receptors (GPCRs) is the PI3 kinase signaling pathway that phosphorylates Akt and activates downstream mTOR and subsequent proliferation. In a large GWAS study, GPCRs were found to be the most frequent signaling pathways involved in PDAC[[52](#_ENREF_52)]. One GPCR, the cholecystokinin (CCK) receptor is over-expressed and ubiquitous in PDAC[[53](#_ENREF_53)]. Stimulation of the CCK receptor accelerates PanIN development in the Kras transgenic mouse model[[54](#_ENREF_54)]. Targeting the CCK receptor has become important in new therapeutics for PDAC and indeed if this receptor is down-regulated growth is inhibited and downstream signaling through PI3 kinase is blocked[[55](#_ENREF_55)].

**TREATMENT**

Treatment options for PDAC patients that present in the late stages are limited to chemotherapy and radiation. Conventional chemotherapeutic agents are ineffective against PDAC for several reasons among which include the microenvironment. PDAC tumors are highly fibrous and poorly vascularized[[13](#_ENREF_13)] prohibiting adequate penetration of the tumor by chemotherapeutic agents. The heterogeneous nature of cancer cells and tissue hypoxia is associated with drug resistance, often requiring higher drug dosages during treatment and increased toxicity such as peripheral neuropathy, bone marrow toxicity, and cardiotoxicity. Gemcitabine is the gold standard for advanced PDAC, but only affords survival up to six months[[56](#_ENREF_56),[57](#_ENREF_57)]. Survival with gemicitabine is, however, improved when administered with other agents[[58](#_ENREF_58)]. Capecitabine and 5-fluorouracil[[59](#_ENREF_59),[60](#_ENREF_60)] are also common antimetabolites administered in clinical trials as a standard single-drug treatment[[61](#_ENREF_61)]. These agents have been used in conjunction with platinum-based agents and other cancer drugs such as leucovorin, exactecan, and irinotecan[[5](#_ENREF_5)]. Radiation therapy is recommended in conjunction as an adjuvant and a chemosensitizer[[62](#_ENREF_62),[63](#_ENREF_63)]. Clinical trials that administer combined drug therapy such as FOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) have shown greater efficacy for metastatic cancer, but with profound limitations due to systemic toxicity and neurotoxicity[[64-67](#_ENREF_64)]. Recently, survival of PDAC patients has been marginally improved by using a combination of nab-Paclitaxel plus gemcitabine[[58](#_ENREF_58)].

Patients may be offered surgery in absence of metastatic spread as determined by positron emission tomography, magnetic resonance imaging, and triphasic computed tomography scans. The Whipple operation is performed on pancreatic cancer involving the head of the pancreas if the superior mesenteric vessels are not affected[[6](#_ENREF_6),[68](#_ENREF_68)]. Pylorus preserving Whipple operation involves removing the first section of the duodenum while others may undergo the standard Whipple operations which involve the removal of a part of the stomach. Adjuvant chemotherapy and radiation therapy usually follow the resection in an attempt to decrease relapse rates. Preoperative chemotherapy and radiation therapy can sometimes restage tumors and make them amenable to surgical resection, but patients with locally advanced pancreatic cancer from the body and tail of the pancreas are often not qualified for surgery due to metastatic spread to the celiac artery. Evidently, surgery assures the longest survival, but promise for full recovery from advanced PDAC is not yet feasible[[69](#_ENREF_69),[70](#_ENREF_70)].

**FUTURE DIRECTIONS BASED ON NANOMEDICINE**

Novel approaches for pancreatic cancer therapy are desperately needed. The trinity offered by nanomedical approaches to simultaneously seek, treat, and track human cancer is slowly emerging from the basic nanoscience toward clinical deployment to treat pancreatic cancer. Adair *et al*[[71](#_ENREF_71)] reviewed the selection criteria for drug delivery strategies based on several nanomaterial platforms. The selection criteria for nanomaterial drug delivery systems are summarized in Tables 1 and 2. Novel strategies using nanotechnology research may lead to advantages in early detection via bioimaging, specific targeting of cancer cell receptors and effective treatment with lower side effects and drug degradation. There is a great demand to improve current drug delivery procedures to overcome drug resistance without causing serious off target toxicity. Targeting proteins involved with signal transduction is one strategy that is currently under investigation. Studies in growth factor inhibitors (opioid growth factors)[[72](#_ENREF_72),[73](#_ENREF_73)] for biotherapy and biocompatible nanomaterials for drug carrier systems, introduce promising directions towards effective cancer management despite limitations. Novel biomarkers like Plectin-1 (Plec1)[[74](#_ENREF_74)] have been found to be useful in the early detection of small pre-invasive PanIN III lesions and metastases. Such biomarkers provide an advantage in early detection when they are over-expressed in specific organs. It was shown that Plec1 can also be used to safely distinguish PDAC from benign conditions and thus this method is more effective than cross-sectional abdominal and invasive endoscopic imaging techniques. Although a cure for PDAC is not feasible with currently available treatment, research in the next decade will develop better prevention and prognosis modalities to diagnose PDAC and improve chances of survival.

One of the most promising nanomedical approaches reported in recent years is based on a novel material system, calcium phosphosilicate hydrate nanoparticles (CPSNPs), in which encapsulated imaging agents and/or drugs, can be delivered in a targeted manner to a variety of cancers including pancreatic cancer[[71](#_ENREF_71),[75-80](#_ENREF_75)]. For example, Barth *et al*[[81](#_ENREF_81)] have demonstrated that a FDA-approved near infra-red fluorophore, indocyanine green (ICG), also known as Cardio-GreenTM, when encapsulated in the CPSNPs, can be used as a theranostic (*i.e.,* a combined diagnostic and therapeutic) agent for a variety of cancers based on a new cancer diagnosis and treatment strategy designated as photo-immuno nanotherapy (PINT). PINT results resurrection of the immune response of the host animal, permitting the immune system to fight the cancer directly. In an earlier report, Barth *et al*[[82](#_ENREF_82)] also demonstrated that gastrin-10 can be used for targeted delivery of ICG-encapsulated CPSNPs *in vivo* based on an orthotopic graft of a human pancreatic cancer in the athymic murine model. The trigger to release the chemotherapeutic agent is inherent dissolution of the CPSNPs in either the acidic local pH in the fluid surrounding many solid tumor types or, after endosomal uptake of the drug-laden CPSNPs into cancer cells, the decreased pH associated with maturation of endosome to endo-lysosomes. Targeting permits the PINT to be used for efficacious uptake in solid tumors and, in an unprecedented fashion, for non-solid tumor cells such as chronic myeloid leukemia[[78](#_ENREF_78),[81](#_ENREF_81),[82](#_ENREF_82)]. Thus, the combination of early detection with more efficacious delivery and more effective treatment promised by nanomedical approaches is emerging as a viable alternative for pancreatic cancer diagnosis and treatment.

**ACKNOWLEDGEMENTS**

Special thanks goes to Austin J Ross for his additional feedback during manuscript preparation.

**REFERENCES**

1 **Maitra A**, Hruban RH. Pancreatic cancer. *Annu Rev Pathol* 2008; **3**: 157-188 [PMID: 18039136 DOI: 10.1146/annurev.pathmechdis.3.121806.154305]

2 Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Pancreas, cited 2013 11-02. Available from: URL: http://seer.cancer.gov/statfacts/html/pancreas.html

3 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

4 **Muniraj T**, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. *Dis Mon* 2013; **59**: 368-402 [PMID: 24183261 DOI: 10.1016/j.disamonth.2013.08.001]

5 **Stathis A**, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. *Nat Rev Clin Oncol* 2010; **7**: 163-172 [PMID: 20101258 DOI: 10.1038/nrclinonc.2009.236]

6 **Kern SE**, Hruban RH, Hidalgo M, Yeo CJ. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. *Cancer Biol Ther* 2002; **1**: 607-613 [PMID: 12642681]

7 **Nakamura T**, Masuda K, Harada S, Akioka K, Sako H. Pancreatic cancer: Slow progression in the early stages. *Int J Surg Case Rep* 2013; **4**: 693-696 [PMID: 23792484 DOI: 10.1016/j.ijscr.2013.04.040]

8 **Dominguez-Bendala J.** Pancreatic Stem Cells. New York, NY: Humana Press, 2009: 11-33

9 **Liszka L**, Paj¹k J, Mrowiec S, Zieliñska-Paj¹k E, Go³ka D, Lampe P. Precursor lesions of early onset pancreatic cancer. *Virchows Arch* 2011; **458**: 439-451 [PMID: 21369801 DOI: 10.1007/s00428-011-1056-3]

10 **Apte MV**, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. *Gastroenterology* 2013; **144**: 1210-1219 [PMID: 23622130 DOI: 10.1053/j.gastro.2012.11.037]

11 **Korc M**. Driver mutations: a roadmap for getting close and personal in pancreatic cancer. *Cancer Biol Ther* 2010; **10**: 588-591 [PMID: 20716952 DOI: 10.4161/cbt.10.6.13128]

12 **Morris JP**, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. *Nat Rev Cancer* 2010; **10**: 683-695 [PMID: 20814421 DOI: 10.1038/nrc2899]

13 **Oberstein PE**, Olive KP. Pancreatic cancer: why is it so hard to treat? *Therap Adv Gastroenterol* 2013; **6**: 321-337 [PMID: 23814611 DOI: 10.1177/1756283X13478680]

14 **Cameron JL**. Pancreatic Cancer. Canada: American Cancer Society, 2001: 67-86

15 **Foley KM**. Pain syndromes and pharmacologic management of pancreatic cancer pain. *J Pain Symptom Manage* 1988; **3**: 176-187 [PMID: 3192963 DOI: 10.1016/0885-3924(88)90028-0]

16 **American Diabetes Association**. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2013; **36 Suppl 1**: S67-S74 [PMID: 23264425 DOI: 10.2337/dc13-S067]

17 **Sah RP**, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 423-433 [PMID: 23528347 DOI: 10.1038/nrgastro.2013.49]

18 **Pannala R**, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. *Lancet Oncol* 2009; **10**: 88-95 [PMID: 19111249 DOI: 10.1016/S1470-2045(08)70337-1]

19 **Gregor MF**, Hotamisligil GS. Inflammatory mechanisms in obesity. *Annu Rev Immunol* 2011; **29**: 415-445 [PMID: 21219177 DOI: 10.1146/annurev-immunol-031210-101322]

20 **Kahn SE**, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006; **444**: 840-846 [PMID: 17167471 DOI: 10.1038/nature05482]

21 **Myers MG**, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. *Trends Endocrinol Metab* 2010; **21**: 643-651 [PMID: 20846876 DOI: 10.1016/j.tem.2010.08.002]

22 **Biddinger SB**, Kahn CR. From mice to men: insights into the insulin resistance syndromes. *Annu Rev Physiol* 2006; **68**: 123-158 [PMID: 16460269 DOI: 10.1146/annurev.physiol.68.040104.124723]

23 **Cui Y**, Andersen DK. Pancreatogenic diabetes: special considerations for management. *Pancreatology* 2011; **11**: 279-294 [PMID: 21757968 DOI: 10.1159/000329188]

24 **Tisdale MJ**. Cancer cachexia. *Langenbecks Arch Surg* 2004; **389**: 299-305 [PMID: 15168125 DOI: 10.1007/s00423-004-0486-7]

25 **Montgomery RC**, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. *Ann Surg Oncol* 1997; **4**: 551-556 [PMID: 9367020 DOI: 10.1007/BF02305535]

26 **Louhimo J**, Alfthan H, Stenman UH, Haglund C. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. *Oncology* 2004; **66**: 126-131 [PMID: 15138364 DOI: 10.1159/000077438]

27 **Koopmann J**, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. *Clin Cancer Res* 2004; **10**: 2386-2392 [PMID: 15073115 DOI: Doi]

28 **Smith JP**, Harms JF, Matters GL, McGovern CO, Ruggiero FM, Liao J, Fino KK, Ortega EE, Gilius EL, Phillips JA. A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer. *Cancer Biol Ther* 2012; **13**: 164-174 [PMID: 22277584 DOI: 10.4161/cbt.13.3.18698]

29 **Nath S**, Daneshvar K, Roy LD, Grover P, Kidiyoor A, Mosley L, Sahraei M, Mukherjee P. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. *Oncogenesis* 2013; **2**: e51 [PMID: 23774063 DOI: 10.1038/oncsis.2013.16]

30 **Batra SK**, Hollingsworth MA. Expression of the human mucin gene, Muc 1, in normal tissues and metastatic pancreatic tumors. *Int J Pancreatol* 1991; **10**: 287-292 [PMID: 1787340 DOI: 10.1007/BF02924167]

31 **Siroy A**, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H, Baar J. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. *Hum Pathol* 2013; **44**: 2159-2166 [PMID: 23845471 DOI: 10.1016/j.humpath.2013.04.010]

32 **Zhang D**, Gao J, Zhu L, Hu Z, Hou R, Liu S, Tan M, Liu J, Lin B. Chemoresistance Is Associated with MUC1 and Lewis y Antigen Expression in Ovarian Epithelial Cancers. *Int J Mol Sci* 2013; **14**: 11024-11033 [PMID: 23708102 DOI: 10.3390/ijms140611024]

33 **Lin JD**, Hsueh C, Huang BY. Papillary thyroid carcinoma with different histological patterns. *Chang Gung Med J* 2011; **34**: 23-34 [PMID: 21392471]

34 **Lee JT**, Steelman LS, McCubrey JA. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. *Cancer Res* 2004; **64**: 8397-8404 [PMID: 15548710 DOI: 10.1158/0008-5472.CAN-04-1612]

35 **Hidalgo M**. Pancreatic cancer. *N Engl J Med* 2010; **362**: 1605-1617 [PMID: 20427809 DOI: 10.1056/NEJMra0901557]

36 **Dayem Ullah AZ**, Cutts RJ, Ghetia M, Gadaleta E, Hahn SA, Crnogorac-Jurcevic T, Lemoine NR, Chelala C. The pancreatic expression database: recent extensions and updates. *Nucleic Acids Res* 2014; **42**: D944-D949 [PMID: 24163255 DOI: 10.1093/nar/gkt959]

37 **Schaeffer HJ**, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. *Mol Cell Biol* 1999; **19**: 2435-2444 [PMID: 10082509]

38 **Sweet-Cordero A**, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet* 2005; **37**: 48-55 [PMID: 15608639 DOI: 10.1038/ng1490]

39 **Vakiani E**, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. *J Pathol* 2011; **223**: 219-229 [PMID: 21125676 DOI: 10.1002/path.2796]

40 **Sandra F**, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. *Oral Oncol* 2006; **42**: 415-420 [PMID: 16413220 DOI: 10.1016/j.oraloncology.2005.09.009]

41 **Kanzaki H**, Ohtaki A, Merchant FK, Greene MI, Murali R. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. *Exp Mol Pathol* 2013; **94**: 372-379 [PMID: 23219833 DOI: 10.1016/j.yexmp.2012.11.003]

42 **Chang YH**, Lin KD, He SR, Hsieh MC, Hsiao JY, Shin SJ. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. *Metabolism* 2011; **60**: 1064-1069 [PMID: 21251686 DOI: 10.1016/j.metabol.2010.11.002]

43 **Philip PA**. Development of targeted therapies for pancreatic cancer. *Lancet Oncol* 2011; **12**: 206-207 [PMID: 21306954 DOI: 10.1016/S1470-2045(11)70029-8]

44 **Yabuuchi S**, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. *Cancer Lett* 2013; **335**: 41-51 [PMID: 23402814 DOI: 10.1016/j.canlet.2013.01.054]

45 **Esni F**, Ghosh B, Biankin AV, Lin JW, Albert MA, Yu X, MacDonald RJ, Civin CI, Real FX, Pack MA, Ball DW, Leach SD. Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. *Development* 2004; **131**: 4213-4224 [PMID: 15280211 DOI: 10.1242/dev.01280]

46 **Avila JL**, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? *Trends Mol Med* 2013; **19**: 320-327 [PMID: 23545339 DOI: 10.1016/j.molmed.2013.03.003]

47 **Agrawal N**, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* 2011; **333**: 1154-1157 [PMID: 21798897 DOI: 10.1126/science.1206923]

48 **Nakhai H**, Siveke JT, Klein B, Mendoza-Torres L, Mazur PK, Algül H, Radtke F, Strobl L, Zimber-Strobl U, Schmid RM. Conditional ablation of Notch signaling in pancreatic development. *Development* 2008; **135**: 2757-2765 [PMID: 18635610 DOI: 10.1242/dev.013722]

49 **Hanlon L**, Avila JL, Demarest RM, Troutman S, Allen M, Ratti F, Rustgi AK, Stanger BZ, Radtke F, Adsay V, Long F, Capobianco AJ, Kissil JL. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. *Cancer Res* 2010; **70**: 4280-4286 [PMID: 20484026 DOI: 10.1158/0008-5472.CAN-09-4645]

50 **Bolós V**, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. *Endocr Rev* 2007; **28**: 339-363 [PMID: 17409286 DOI: 10.1210/er.2006-0046]

51 **Kim W**, Shin YK, Kim BJ, Egan JM. Notch signaling in pancreatic endocrine cell and diabetes. *Biochem Biophys Res Commun* 2010; **392**: 247-251 [PMID: 20035712 DOI: 10.1016/j.bbrc.2009.12.115]

52 **Wei P**, Tang H, Li D. Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. *PLoS One* 2012; **7**: e46887 [PMID: 23056513 DOI: 10.1371/journal.pone.0046887]

53 **Smith JP**, Solomon TE. Cholecystokinin and pancreatic cancer: the chicken or the egg? *Am J Physiol Gastrointest Liver Physiol* 2014; **306**: G91-G101 [PMID: 24177032 DOI: 10.1152/ajpgi.00301.2013]

54 **Carrière C**, Young AL, Gunn JR, Longnecker DS, Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. *Biochem Biophys Res Commun* 2009; **382**: 561-565 [PMID: 19292977 DOI: 10.1016/j.bbrc.2009.03.068]

55 **Fino KK**, Matters GL, McGovern CO, Gilius EL, Smith JP. Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis. *Am J Physiol Gastrointest Liver Physiol* 2012; **302**: G1244-G1252 [PMID: 22442157 DOI: 10.1152/ajpgi.00460.2011]

56 **Burris HA**, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; **15**: 2403-2413 [PMID: 9196156]

57 **Di Marco M**, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). *Oncol Rep* 2010; **23**: 1183-1192 [PMID: 20372829 DOI: 10.3892/or\_00000749]

58 **Von Hoff DD**, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; **369**: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]

59 **Longley DB**, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. *Nat Rev Cancer* 2003; **3**: 330-338 [PMID: 12724731 DOI: 10.1038/nrc1074]

60 **Diasio RB**, Harris BE. Clinical pharmacology of 5-fluorouracil. *Clin Pharmacokinet* 1989; **16**: 215-237 [PMID: 2656050 DOI: 10.2165/00003088-198916040-00002]

61 **McKenna S**, Eatock M. The medical management of pancreatic cancer: a review. *Oncologist* 2003; **8**: 149-160 [PMID: 12697940 DOI: 10.1634/theoncologist.8-2-149]

62 **Wang F**, Kumar P. The role of radiotherapy in management of pancreatic cancer. *J Gastrointest Oncol* 2011; **2**: 157-167 [PMID: 22811846 DOI: 10.3978/j.issn.2078-6891.2011.032]

63 **Hazard L**. The role of radiation therapy in pancreas cancer. *Gastrointest Cancer Res* 2009; **3**: 20-28 [PMID: 19343134]

64 **Joseph R**, Dasanu CA. A curious case of oxaliplatin-induced neurotoxicity: Recurrent, self-limiting dysarthria. *J Oncol Pharm Pract* 2013; In press [PMID: 24103898 DOI: 10.1177/1078155213506477]

65 **Vaccaro V**, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; **365**: 768-79; author reply 769 [PMID: 21864184 DOI: 10.1056/NEJMc1107627#SA1]

66 **Gourgou-Bourgade S**, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. *J Clin Oncol* 2013; **31**: 23-29 [PMID: 23213101 DOI: 10.1200/JCO.2012.44.4869]

67 **Conroy T**, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; **364**: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]

68 **Shrikhande SV**, Barreto SG. Surgery for pancreatic carcinoma: state of the art. *Indian J Surg* 2012; **74**: 79-86 [PMID: 23372311 DOI: 10.1007/s12262-011-0373-8]

69 **Falconi M**, Mantovani W, Bettini R, Talamini G, Bassi C, Cascinu S, Oliani C, Pederzoli P. Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade? *Dig Liver Dis* 2003; **35**: 421-427 [PMID: 12868679]

70 **Vincent A**, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. *Lancet* 2011; **378**: 607-620 [PMID: 21620466 DOI: 10.1016/S0140-6736(04)15841-8]

71 **Adair JH**, Parette MP, Altinoðlu EI, Kester M. Nanoparticulate alternatives for drug delivery. *ACS Nano* 2010; **4**: 4967-4970 [PMID: 20873786 DOI: 10.1021/nn102324e]

72 **Smith JP**, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. *Anticancer Drugs* 2004; **15**: 203-209 [PMID: 15014352]

73 **Zagon IS**, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. *Cancer Chemother Pharmacol* 2005; **56**: 510-520 [PMID: 15947928 DOI: 10.1007/s00280-005-1028-x]

74 **Bausch D**, Thomas S, Mino-Kenudson M, Fernández-del CC, Bauer TW, Williams M, Warshaw AL, Thayer SP, Kelly KA. Plectin-1 as a novel biomarker for pancreatic cancer. *Clin Cancer Res* 2011; **17**: 302-309 [PMID: 21098698 DOI: 10.1158/1078-0432.CCR-10-0999]

75 **Tabakoviæ A**, Kester M, Adair JH. Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. *Wiley Interdiscip Rev Nanomed Nanobiotechnol* 2012; **4**: 96-112 [PMID: 21965173 DOI: 10.1002/wnan.163]

76 **Altinoðlu EI**, Adair JH. Near infrared imaging with nanoparticles. *Wiley Interdiscip Rev Nanomed Nanobiotechnol* 2010; **2**: 461-477 [PMID: 20135691 DOI: 10.1002/wnan.77]

77 **Altinoðlu EI**, Russin TJ, Kaiser JM, Barth BM, Eklund PC, Kester M, Adair JH. Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for *in vivo* imaging of human breast cancer. *ACS Nano* 2008; **2**: 2075-2084 [PMID: 19206454 DOI: 10.1021/nn800448r]

78 **Barth BM**, I Altinoðlu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP, Claxton DF, Kester M. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for *in vivo* photodynamic therapy of leukemia. *ACS Nano* 2011; **5**: 5325-5337 [PMID: 21675727 DOI: 10.1021/nn2005766]

79 **Kester M**, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoðlu EI, Tabakoviæ A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for *in vitro* imaging and encapsulated chemotherapeutic drug delivery to cancer cells. *Nano Lett* 2008; **8**: 4116-4121 [PMID: 19367878 DOI: 10.1021/nl802098g]

80 **Morgan TT**, Muddana HS, Altinoglu EI, Rouse SM, Tabakoviæ A, Tabouillot T, Russin TJ, Shanmugavelandy SS, Butler PJ, Eklund PC, Yun JK, Kester M, Adair JH. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. *Nano Lett* 2008; **8**: 4108-4115 [PMID: 19367837 DOI: 10.1021/nl8019888]

81 **Barth BM**, Shanmugavelandy SS, Kaiser JM, McGovern C, Altýnoðlu EÝ, Haakenson JK, Hengst JA, Gilius EL, Knupp SA, Fox TE, Smith JP, Ritty TM, Adair JH, Kester M. PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphate. *ACS Nano* 2013; **7**: 2132-2144 [PMID: 23373542 DOI: 10.1021/nn304862b]

82 **Barth BM**, Sharma R, Altinoðlu EI, Morgan TT, Shanmugavelandy SS, Kaiser JM, McGovern C, Matters GL, Smith JP, Kester M, Adair JH. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers *in vivo*. *ACS Nano* 2010; **4**: 1279-1287 [PMID: 20180585 DOI: 10.1021/nn901297q]

83 **Ferrari M**. Nanogeometry: beyond drug delivery. *Nat Nanotechnol* 2008; **3**: 131-132 [PMID: 18654480 DOI: 10.1038/nnano.2008.46]

84 **Yih TC**, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. *J Cell Biochem* 2006; **97**: 1184-1190 [PMID: 16440317 DOI: 10.1002/jcb.20796]


85 **Inzana JA**, Olvera D, Fuller SM, Kelly JP, Graeve OA, Schwarz EM, Kates SL, Awad HA. 3D printing of composite calcium phosphate and collagen scaffolds for bone regeneration. *Biomaterials* 2014; **35**: 4026-4034 [PMID: 24529628 DOI: 10.1016/j.biomaterials.2014.01.064]

86 **Hribar KC**, Soman P, Warner J, Chung P, Chen S. Light-assisted direct-write of 3D functional biomaterials. *Lab Chip* 2014; **14**: 268-275 [PMID: 24257507 DOI: 10.1039/c3lc50634g]


87 **Koutsopoulos S**. Molecular fabrications of smart nanobiomaterials and applications in personalized medicine. *Adv Drug Deliv Rev* 2012; **64**: 1459-1476 [PMID: 22921596 DOI: 10.1016/j.addr.2012.08.002]

**P-Reviewers:** Ding XW, Gangl A, Miyagawa S, Massironi S, Tu H **S-Editor:** Gou SX

**L-Editor: E-Editor:**



**Figure 1 Example of pancreatic intraepithelial neoplasia** **lesion development to pancreatic ductal adenocarcinoma.** Inflammatory stimuli trigger the activation of pancreatic stellate cells (PaSC) surrounding acinus cells. Inflammatory cells (monocytes, T-cells, neutrophils, mast cells, and macrophages) gather in response and release ligands (interleukin-6) that activate *STAT3* gene to promote pancreatic intraepithelial neoplasia (PanIN) development in susceptible tissue with oncogenic mutations such as the Kras. PDAC: Pancreatic ductal adenocarcinoma. Figure redrawn with permissions from Elsevier: [[10](#_ENREF_10)] and Macmillan Publishers Ltd: [[12](#_ENREF_12)].



**Figure 2 Symptoms of paraneoplastic type 3c diabetes preceding pancreatic cancer.** A: A comparison of weight-loss timeline to cancer-specific symptoms; B: Schematic representation of the cause for progressive weight reduction and insulin resistance. Adipose tissue inflammation triggers an alteration of adipocyte secretion and propagates pathogenic processes similar to type 2 diabetes, eventually leading to cachexia. Figures redrawn with permission from Macmillan Publishers Ltd: [[17](#_ENREF_17)].

**Table 1 Desired characteristics for a nanoparticle drug-delivery platform**

|  |  |
| --- | --- |
| **Desired characteristic** | **Comments** |
| Inherently non-toxic materials and degradation products | The initial material selection should be based on non-toxic materials especially with an aim toward human health care |
| Small size (10–200 nm) | There is not a particular size that seems most efficacious, particularly based on *in vivo* studies. This is the range of particle diameters that have proven most effective for a wide variety of delivery systems. Also of note is the debate around the influence of particle shape[[83](#_ENREF_83)] |
| Encapsulation of active agent | To be effective, the active agent must be encapsulated within the nanoparticle vehicle. Surface decoration (*i.e.,* adsorption) will often be effective *in vitro* but falls short for *in vivo* studies because of the reticuloendoplasmic systems *in vivo* |
| Colloidally stable in physiological conditions | The nanoparticle vehicle and surface functionalization must resist agglomeration for the solution pH values, ionic strength, macromolecular interactions, and temperature encountered in the physiological environment |
| Clearance mechanism | The nanoparticle vehicle must have a ready clearance mechanism to avoid the cumulative and/or systemic effects of the drug-laden particles |
| Long clearance times | Resistance to agglomeration and other effects that remove the nanoparticle-encapsulated drug from the patient must be avoided to promote long circulation times in the circulatory system for as many of the nanoparticles to find and sequester in the cancer cells as possible |
| Biologically or extrinsically controlled release of therapeutic agents | There should be a trigger mechanism such as the acidic pH within the tumor or during endosome maturation designed into the nanoparticle platform to ensure the release of the encapsulated drug into the targeted tissue |
| Can be targeted to cell/tissue of choice | The nanoparticle platform should be capable of surface bioconjugation to target molecules for the specific cancer to provide the greatest uptake with the lesions and fewest least side effects with healthy tissue |

Reprinted with permission from [[71](#_ENREF_71)]. Copyright 2010 American Chemical Society.

**Table 2 The selection criteria for nanomaterial drug delivery systems**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nano particulate material** | **Size (nm)** | **Therapeutic agent(s) carried** | **Advantages** | **Limitations** |
| Biodegradable polymers | 10-100 | Plasmid DNA, proteins, peptides, low molecular-weight (MW) organic compounds | Sustained localized drug delivery for weeks | Exocytosis of undissolved nanoparticles. Fixed functionality after synthesis may require new synthetic pathways for alternate surface functionalities |
| Ceramic | < 100 | Proteins, DNA, chemotherapeutic agents, high MW organic compounds | Easily prepared, water dispersible, stable in biological environments | Toxicity of materials, exocytosis of undissolved nanoparticles, time consuming synthesis, surface decoration instead of encapsulation |
| Metals | < 50 | Proteins, DNA, chemotherapeutic agents | Small particles present a large surface area for surface decoration delivery | Toxicity of materials, exocytosis of undissolved nanoparticles, time consuming synthesis, surface decoration instead of encapsulation |
| Polymeric micelles | < 100 | Proteins, DNA, chemotherapeutic agents | Suitable for water-insoluble drugs due to hydrophobic core | Toxicity of materials, fixed functionality after synthesis |
| Dendrimers | < 10 | Chemotherapeutic agents, anti-bacterial, anti-viral agents, DNA, high MW organic compounds | Suitable for hydrophobic or hydrophilic drugs | May use toxic materials, time consuming synthesis, fixed functionality after synthesis may require new synthetic pathways for alternate surface functionalities |
| Liposomes | 50-100 | Chemotherapeutic agents, proteins, DNA | Reduced systemic toxicity, increased circulation time | Fixed functionality after synthesis, some leakage of encapsulated agent, lack of colloidal stability |
| 3D Printing | 20-2000 | Chemotherapeutic agents, proteins, DNA, imaging agents | Precise control over size, shape, and surface functionalization. 3D printing can be used with an array of processing techniques to create porous scaffolds[[85](#_ENREF_85)] and lab-on-chip devices[[86](#_ENREF_86)] for personalized medicine[[87](#_ENREF_87)] | Toxicity of materials depending on material |
| Calcium phosphosilicate | 20-60 | Chemotherapeutic agents, RNA, high and low MW organic compounds, imaging agents | Simple preparation, suitable for hydrophilic or hydrophobic drugs, colloidal stability in physiological environments, pH-dependent dissolution results in intracellular delivery of drugs, composed of bio-resorbable material | Encapsulated materials limited to solubility in water or organic solvent |

Reprinted and updated with permission from [71] which contains material adapted from [84]. Copyright 2010 American Chemical Society.